Results 81 to 90 of about 7,183 (232)

Uso de trombolíticos e associações farmacológicas no tratamento do acidente vascular cerebral isquêmico agudo : revisão sistemática e meta-análise em rede [PDF]

, 2017
Dissertação (mestrado)—Universidade de Brasília, Faculdade de Ciências da Saúde, Programa de Pós-Graduação em Ciências da Saúde, 2017.Introdução: O acidente vascular cerebral isquêmico (AVCi) é uma das principais causas de mortalidade e incapacidade ...
Brito, Gabriela Vilela de
core  

Initial experience with the left ventricular assist device TransCoreTM [PDF]

, 2010
Cardiogenic shock is a condition associated to high mortality rates. For decades, the treatment consisted of vasoactive drugs and intra-aortic balloon pump.
Alves, Claudia Maria Rodrigues, Lima, Valter Correia De, Minohara, Stéfano Franco, Souza, Cristiano Freitas De   +3 more
core   +1 more source

Mechanical Thrombectomy for TRACE‐III‐Eligible Patients With Ischemic Stroke: A Multicenter Retrospective Study Compared to TRACE‐III and TIMELESS Trials

Annals of Clinical and Translational Neurology, Volume 12, Issue 9, Page 1886-1893, September 2025.
ABSTRACT Objective The results of the TRACE‐III trial demonstrated that tenecteplase (TNK) might be comparable to TNK combined with mechanical thrombectomy (MT) for large vessel occlusion (LVO) stroke within 4.5 to 24 h of onset, as tested in the TIMELESS trial.
Chongyang Huang, Yanru Liu, Jiangang Zhang, Sheng Guan, Tao Quan, Zhen Chen, Xiaojie Fu, Sen Wei, Kaihao Han, Xiaoan Zhou, Chengcheng Zhu, Edgar Samaniego, Yueqi Zhu, Haowen Xu   +13 more
wiley   +1 more source

A Systematic Review of the Efficacy and Safety of Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Time to Pass the Torch

Stroke: Vascular and Interventional Neurology
Alteplase, a biosynthetic form of human tissue‐type plasminogen activator, is Food and Drug Administration‐approved for the treatment of acute ischemic stroke and currently the standard of care for thrombolytic therapy.
Miguel Rodriguez, Christian Sidebottom, Drew A. Wells, Thirumalaivasan Dhasakeerthi, Lisa Hayes, Cheran Elangovan, Balaji Krishnaiah   +6 more
doaj   +1 more source

Circulating Interleukin‐6 Levels and Timing of Acute Ischemic Stroke Onset

Annals of Clinical and Translational Neurology, Volume 12, Issue 9, Page 1926-1931, September 2025.
ABSTRACT Intravenous thrombolysis is the most widely available effective ischemic stroke treatment, but is approved only if given within 4.5 h from stroke onset. Many patients are not treated because stroke onset time is unknown. We evaluated the cytokine interleukin 6 (IL‐6) in circulating blood after acute ischemic stroke (AIS).
Robert G. Kowalski, Aurélie Ledreux, John E. Violette, Whitney Paustian, Stefan Sillau, John A. Thompson, Robert T. Neumann, David Ornelas, Andrew A. Monte, Layne Dylla, Adit A. Ginde, Andra M. Farcas, Christina M. Coughlan, William J. Jones, James C. Grotta, Michael W. Graner   +15 more
wiley   +1 more source

Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke: subgroup analysis of the TRACE-2 randomised controlled clinical trial

Stroke and Vascular Neurology
Background The benefit of intravenous alteplase in acute ischaemic stroke (AIS) is time-dependent. Tenecteplase is non-inferior to alteplase among patients with AIS.
Bruce C V Campbell, Yongjun Wang, Yilong Wang, Zixiao Li, Xingquan Zhao, David Wang, Yunyun Xiong, Hao Li, Xia Meng, Yuesong Pan, Lee H Schwamm, Aoming Jin, Mark W Parsons, Huaguang Zheng, Shuya Li, Runhui Li, Marc Fisher, Runqi Wangqin, Ziran Wang, Deyang Li, Hongguo Dai, Junhai Wang   +21 more
doaj   +1 more source

Reduction of Steroid-Induced Intraocular Pressure Elevation in Sheep by Tissue Plasminogen Activator [PDF]

, 2013
PURPOSE. To investigate whether tissue plasminogen activator (tPA) can prevent and/or reverse steroid-induced IOP elevation in an ovine model. METHODS.
Alvarez, Larry, Candia, Oscar, Danias, John, Gerometta, Rosana María del Rosario, Kumar, Sandeep, Shah, Shaily   +5 more
core   +2 more sources

Alteplase- and Tenecteplase-Related Errors and Risk Mitigation Strategies in the Treatment of Acute Ischemic Stroke: A Study of Event Reports From 52 Hospitals

Patient Safety
# Background Alteplase and tenecteplase are thrombolytic agents used to treat patients with acute ischemic stroke (AIS). Despite the convenient bolus dosing of tenecteplase, its off-label use for AIS creates new patient safety challenges that are ...
Myungsun Ro, Matthew A. Taylor, Rebecca Jones   +2 more
doaj   +1 more source

Tenecteplase: biochemical and clot lysis activity comparisons

Frontiers in Pharmacology
IntroductionIn the last decades, the recombinant tissue plasminogen activator alteplase has been the standard fibrinolytic treatment of acute myocardial infarction, pulmonary embolism, and acute ischemic stroke.
Jan Bechmann, Ira Schmid, Simone Brand, Felix Miller, Chengzhi Zhang   +4 more
doaj   +1 more source

Implementation of a Tenecteplase Protocol for Treatment of Acute Ischemic Stroke in a Health System

INNOVATIONS in Pharmacy
Purpose. Alteplase is the standard of care for intravenous thrombolytic treatment of acute ischemic stroke, but recent evidence suggests that tenecteplase may be as safe and efficacious. The purpose of this study was to evaluate the direct cost savings,
Alexis Pace, Maya Wai, Ethan Frye
doaj